Ireland-based biopharmaceutical company Jazz Pharmaceuticals has begun enrolment in its Phase II clinical trial of JZP-110 to treat excessive sleepiness (ES) in adult patients with Parkinson's disease.
JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) designed to treat adult patients with narcolepsy or obstructive sleep apnea (OSA).
Go deeper with GlobalData
Expected to enrol up to 50 patients, the double-blind, placebo-controlled, randomised, multicentre, cross-over trial will evaluate the safety, efficacy and pharmacokinetics of the drug.
Jazz Pharmaceuticals research and development global head Karen Smith said: "Excessive sleepiness is a debilitating symptom of Parkinson's disease, and we are interested in determining whether the wake-promoting effects of JZP-110 could be beneficial in this patient population.
"The initiation of this study is another step forward in our development programme for JZP-110 and our efforts to develop new treatment options for people with sleep disorders."
Parkinson's disease is a chronic neurodegenerative brain disorder with motor and non-motor symptoms such as ES, which may result in an enhanced risk for falls and motor vehicle accidents.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe JZP-110 is being studied in a Phase III clinical trial programme, which includes two studies evaluating ES in adult patients with OSA, one study evaluating ES in adult patients with narcolepsy and an open-label long-term safety study.
While the enrolment has been closed in the OSA and narcolepsy studies, the open-label study is currently enrolling subjects.
With the orphan drug designation in the US for narcolepsy, Jazz Pharmaceuticals holds the development, manufacturing, and commercialisation rights to JZP-110, except in certain Asian jurisdictions.
